Abstract
Non-invasive methods of inducing a miscarriage are now considered an effective alternative to surgical evacuation (dilatation and curettage). This study aimed to evaluate the effectiveness of misoprostol in the termination of first-trimester miscarriages. This prospective study was conducted between October 2009 and September 2010 and assessed all patients admitted to the Royal Hospital in Muscat, Oman, for the termination of first-trimester miscarriages during the study period. All patients received misoprostol and the rates of successful termination were measured. Patient satisfaction was assessed using a short questionnaire. A total of 290 women were included in the study. Termination with misoprostol was successful in 61.38% of the subjects. Of the remaining subjects requiring additional surgical evacuation (n = 112), 58.93% required evacuation due to failed termination with misoprostol and 65.18% underwent early evacuation (≤24 hours since their last misoprostol dose). The majority of patients experienced no side-effects due to misoprostol (89.66%). Pain was controlled with simple analgesics in 70.00% of the subjects. A high satisfaction rate (94.83%) with the misoprostol treatment was reported. Misoprostol was a well-tolerated drug which reduced the rate of surgical evacuation among the study subjects. This medication can therefore be used safely in the management of incomplete miscarriages.
Highlights
Non-invasive methods of inducing a miscarriage are considered an effective alternative to surgical evacuation
This study aimed to evaluate the effectiveness of misoprostol in the termination of first-trimester miscarriages
This prospective study was conducted between October 2009 and September 2010 and assessed all patients admitted to the Royal Hospital in Muscat, Oman, for the termination of first-trimester miscarriages during the study period
Summary
Abstract: Objectives: Non-invasive methods of inducing a miscarriage are considered an effective alternative to surgical evacuation (dilatation and curettage). Misoprostol is a synthetic prostaglandin E1 analogue which causes uterine contractions and softening and dilation of the cervix It has been used offlabel in the management of miscarriage, postpartum haemorrhage, induction of labour and ripening of the cervix.[3] misoprostol is not yet licensed by the Food and Drug Administration in the USA for the above indications, pregnancy was removed from the list of absolute contraindications to misoprostol use in 2002.4 The advantages of misoprostol include its low cost, long shelf life, lack of need for refrigeration and worldwide availability.[3] The aim of this study was to evaluate the success of misoprostol as an agent for medical termination in first-trimester miscarriages at the Royal Hospital, Muscat, Oman
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
